Compare FirstEnergy Corp. (FE) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FirstEnergy Corp. vs TG Therapeutics Inc — how do they compare? FirstEnergy Corp. trades at $46.86 (market cap $27.10B), while TG Therapeutics Inc trades at $49.44 (market cap $7.64B). The key difference: FirstEnergy Corp. is far larger — about 3.5× TG Therapeutics Inc's market cap, and FirstEnergy Corp. pays a 3.97% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| FE | TGTX | |
|---|---|---|
Market Cap | $27.10B | $7.64B |
Sector | Utilities | Health |
52-Week High | $51.91 | $59.06 |
52-Week Low | $42.83 | $26.94 |
Enterprise Value | $56.02B | $7.84B |
Dividend Yield | 3.97% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FirstEnergy (FE) trades at $46.95, up 0.41% with a bearish technical outlook despite recent earnings beats. The utility company shows steady revenue growth to $15.09B in 2025 and maintains a 6.86% net margin, though earnings have been mixed with two recent misses. Analyst sentiment is cautiously optimistic with a $52.67 price target, while institutional buying activity indicates confidence in the company's $36B grid investment plan and data center demand growth.
FE presents a defensive investment opportunity with visible earnings growth from infrastructure investments, but faces execution risks on capital projects and regulatory uncertainty. The stock's current valuation at 25x P/E appears reasonable given the 6-8% EPS growth guidance, though high debt levels and interest expenses remain concerns for margin expansion.
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About FirstEnergy Corp.
FirstEnergy is one of the largest investor-owned utilities in the United States with 10 regulated distribution companies across six mid-Atlantic and Midwestern states. FirstEnergy also owns and operates one of the nation's largest electric transmission systems with 24,000 miles of lines.
Read more on FE →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
